Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Sweden
Brand Name : Mozobil
Dosage Form : INJEKTIONSVÄTSKA, LÖSNING
Dosage Strength : 20 MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Italy
Brand Name : Mozobil
Dosage Form : Plerixafor 24Mg 1,2Ml 1 Unit Parenteral Use
Dosage Strength : 1 bottle SC 24 mg 20 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Norway
Brand Name : Mozobil
Dosage Form : Injection fluid, resolution
Dosage Strength : 20 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 24MG/1.2ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 20MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.
Regulatory Info :
Registration Country : Iran
Brand Name : Neofor
Dosage Form : Vial
Dosage Strength : 24MG/1.2ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 24MG/1.2ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 20MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finished Drug Prices
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class H
Dosage Form : Plerixafor 24Mg 1,2Ml 1 Unit Par...
Dosage Strength : 1 bottle SC 24 mg 20 mg/ml
Price Per Pack (Euro) : 9,257.16
Published in :
Country : Italy
RX/OTC/DISCN : Class H
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN :
Dosage Form : Injection fluid, resolution
Dosage Strength : 20 mg/ml
Price Per Pack (Euro) : 7,139.36
Published in :
Country : Norway
RX/OTC/DISCN :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 216
2018 Revenue in Millions : 186
Growth (%) : 16
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 259
2019 Revenue in Millions : 239
Growth (%) : 8
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 257
2020 Revenue in Millions : 233
Growth (%) : 9
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 286
2021 Revenue in Millions : 257
Growth (%) : 12
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 237
2022 Revenue in Millions : 286
Growth (%) : -16
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 9.90%
2013 Revenue in Millions :
Growth (%) :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 122
2014 Revenue in Millions : 157
Growth (%) : 29%
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 161
2015 Revenue in Millions : 152
Growth (%) : 6
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 202
2016 Revenue in Millions : 188
Growth (%) : 7
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 193
2017 Revenue in Millions : 184
Growth (%) : 5%
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Plerixafor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Plerixafor, including repackagers and relabelers. The FDA regulates Plerixafor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Plerixafor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Plerixafor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Plerixafor supplier is an individual or a company that provides Plerixafor active pharmaceutical ingredient (API) or Plerixafor finished formulations upon request. The Plerixafor suppliers may include Plerixafor API manufacturers, exporters, distributors and traders.
click here to find a list of Plerixafor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Plerixafor DMF (Drug Master File) is a document detailing the whole manufacturing process of Plerixafor active pharmaceutical ingredient (API) in detail. Different forms of Plerixafor DMFs exist exist since differing nations have different regulations, such as Plerixafor USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Plerixafor DMF submitted to regulatory agencies in the US is known as a USDMF. Plerixafor USDMF includes data on Plerixafor's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Plerixafor USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Plerixafor suppliers with USDMF on PharmaCompass.
A Plerixafor written confirmation (Plerixafor WC) is an official document issued by a regulatory agency to a Plerixafor manufacturer, verifying that the manufacturing facility of a Plerixafor active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Plerixafor APIs or Plerixafor finished pharmaceutical products to another nation, regulatory agencies frequently require a Plerixafor WC (written confirmation) as part of the regulatory process.
click here to find a list of Plerixafor suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Plerixafor as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Plerixafor API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Plerixafor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Plerixafor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Plerixafor NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Plerixafor suppliers with NDC on PharmaCompass.
Plerixafor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Plerixafor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Plerixafor GMP manufacturer or Plerixafor GMP API supplier for your needs.
A Plerixafor CoA (Certificate of Analysis) is a formal document that attests to Plerixafor's compliance with Plerixafor specifications and serves as a tool for batch-level quality control.
Plerixafor CoA mostly includes findings from lab analyses of a specific batch. For each Plerixafor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Plerixafor may be tested according to a variety of international standards, such as European Pharmacopoeia (Plerixafor EP), Plerixafor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Plerixafor USP).
LOOKING FOR A SUPPLIER?
